The invention provides compositions and methods for laser actuated drug delivery. Compositions comprise serum albumin based particles conjugated with therapeutic agents which cab become bioavailable upon actuation of the particles by light, e.g. low power laser.

Compositions are provided in which dendrimers and/or nanoparticles are synthesized with multi-photon responsive elements and self-immolative oligomers. The compositions may be utilized to selectively deliver Payloads within tissue by irradiating the compositions. The compositions may also be used to amplify sensitivity to irradiation.

There are provided, inter alia, compositions including a scintillator nanocrystal linked to a chemical agent moiety through a scintillator-activated photocleavable linker, and methods of use thereof.

A responsive hydrogel-based material may be used as a carrier system for the in situ delivery of various cargo substances, including bioactive moieties. The hydrogel structure, which includes photodegradable and thioether moieties in its three dimensional network, enables finely tuned local release of cargo substances as a function of the in vivo tissue environment (e.g., enzyme concentration or reducing environment) and externally applied stimuli (e.g., light) by selective spatiotemporal hydrogel degradation.

The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of a cell using a photochemical internalisation method in which a cytokine, preferably GM-CSF, is used to enhance the method. The method may be used to stimulate an immune response and for various therapeutic or prophylactic methods. Pharmaceutical compositions or kits comprising the components for use in the method, cells produced by the method and their use in therapy and prophylaxis also form aspects of the invention.

The present invention relates to photohexer compounds and a pharmaceutical composition and use thereof. Specifically, the present invention relates to 2(4)-(1-hexyloxy-ethyl)-6,7-bispropionate-1,3,5,8-tetramethyl-4(2)-vinylpor-phyrin and their analogues, which are water soluble, have stable properties, can be used as a photosensitizer, and are suitable for the diagnosis and treatment of malignant tumors, precancerous lesions or benign lesions. The invention also relates to pharmaceutical compositions comprising such novel compounds, their use and preparation methods.

A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.

The invention relates to the field of medicine and medicinal chemistry, more in particular to the design, manufacture and use of anti-cancer drugs that can be activated by an external stimulus that can be applied in a spatiotemporal fashion. Provided herein is a compound having the chemical structure

##STR00001##

or a pharmaceutically acceptable salt thereof.

A triggerable polymeric nanoparticle (NP) library composed by several formulations, presenting physico-chemical diversity and differential responsiveness to light. In certain applications, six formulations were more efficient (up to 500%) than commercial Lipofectamine in gene knockdown activity. These formulations had differential internalization by skin cells and the endosomal escape was rapid (minutes range) as shown by the recruitment of galectin 8. The NPs described were effective in the release of siRNA and miRNA but can also be extended to the release of mRNA and other types of RNA. Acute skin wounds treated with the top hit NP complexed with miRNA-150-5p healed faster than wounds treated with scramble miRNA. Thus, light-triggerable NPs offer a new strategy to deliver topically non-coding and coding RNAs.

Crosslinkers of an amide or thiocarbamate of 7-nitroindoline were prepared with at least two attached reactive groups for crosslinking capability. The photo-cleavability of the invented crosslinkers is based on the known photolysis behavior of N-acyl-7-nitroindolines, and the photolysis behavior of amides and thiocarbamates of 7-nitroindolines. These crosslinkers enable crosslinking of biopolymers, which can be reversed by illumination with light.